Resmetirom
Phase 3Active 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Non-Alcoholic Fatty Liver Disease
Conditions
Non-Alcoholic Fatty Liver Disease
Trial Timeline
Jul 9, 2021 → Apr 1, 2026
NCT ID
NCT04951219About Resmetirom
Resmetirom is a phase 3 stage product being developed by Madrigal Pharmaceuticals for Non-Alcoholic Fatty Liver Disease. The current trial status is active. This product is registered under clinical trial identifier NCT04951219. Target conditions include Non-Alcoholic Fatty Liver Disease.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04951219 | Phase 3 | Active |
Competing Products
20 competing products in Non-Alcoholic Fatty Liver Disease